Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have been adopted to treat several kinds of malignancies. Autoimmune diseases (AIDs), a class of chronic disease conditions, can be broadly separated into autoantibody-mediated and T cell-mediated diseases. Treatments for AIDs are focused on restoring immune tolerance. However, current treatments have little effect on immune tolerance inverse; even the molecular target biologics like anti-TNFαinhibitors can only mildly restore immune balance. By using the idea of CAR-T cell treatment in tumors, CAR-T cell-derived immunotherapies, chimeric autoantibody receptor T (CAAR-T) cells, and CAR regulatory T (CAR-T) cells bring new hope of treatment choice for AIDs.
Funding Information
  • Application Foundation Project in Sichuan Province (2017JY0025, 2016JY0021, ZYJC18021, 81172869, 30901339)
  • Application Foundation Project in Sichuan Province (2017JY0025, 2016JY0021, ZYJC18021, 81172869, 30901339)
  • Sichuan University (2017JY0025, 2016JY0021, ZYJC18021, 81172869, 30901339)
  • National Natural Science Foundation of China (2017JY0025, 2016JY0021, ZYJC18021, 81172869, 30901339)
  • National Natural Science Foundation of China (2017JY0025, 2016JY0021, ZYJC18021, 81172869, 30901339)

This publication has 74 references indexed in Scilit: